2019
Clinical utility of genomic analysis in adults with idiopathic liver disease
Hakim A, Zhang X, DeLisle A, Oral EA, Dykas D, Drzewiecki K, Assis DN, Silveira M, Batisti J, Jain D, Bale A, Mistry PK, Vilarinho S. Clinical utility of genomic analysis in adults with idiopathic liver disease. Journal Of Hepatology 2019, 70: 1214-1221. PMID: 31000363, PMCID: PMC6526061, DOI: 10.1016/j.jhep.2019.01.036.Peer-Reviewed Original ResearchConceptsIdiopathic liver diseaseUnexplained liver diseaseManagement of adultsWhole-exome sequencingLiver diseaseAdult patientsUnknown etiologyHeterozygous variantsUse of WESAmelioration of dyslipidemiaDaily insulin requirementLeptin replacement therapyUtility of WESChronic liver diseaseNon-alcoholic steatohepatitisAcademic health care centerHealth care centersHomozygous pathogenic variantUnrelated adult patientsNon-oncological diseasesDisease preventive measuresInsulin requirementsLean patientsDevastating complicationLiver aminotransferases
2011
Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation
Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation. Transplantation Proceedings 2011, 43: 905-908. PMID: 21486625, DOI: 10.1016/j.transproceed.2011.02.034.Peer-Reviewed Case Reports and Technical NotesConceptsLiver allograft rejectionHepatitis C virusRenal graft rejectionAllograft rejectionHCV recurrenceCholestatic hepatitisGraft rejectionHCV RNAPatient survivalEnd-stage liver disease (MELD) scoreOne-year patient survivalIFN/RBV therapyFIBROSING CHOLESTATIC HEPATITISHistologic HCV recurrenceIFN/ribavirinOne-year graftSuccessful salvage strategiesTime of OLTHCV RNA levelsLiver Disease scoreAnti-HCV therapyCohort of patientsEarly graft failureFCH groupOLT recipients